Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site. # Citryll ## Sitemaps - [XML Sitemap](https://citryll.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [New research published in Frontiers in Immunology highlights CIT-013’s ability to modulate macrophage responses and promote inflammation resolution](https://citryll.com/new-research-published-in-frontiers-in-immunology-highlights-cit-013s-ability-to-modulate-macrophage-responses-and-promote-inflammation-resolution/) - Citryll has published new preclinical research that deepens the understanding of how CIT-013, the Company’s first-in-class monoclonal antibody, modulates immune responses in inflammatory disease. The study shows that CIT-013 not only enhances the clearance of extracellular traps (ETs), but also modulates macrophage behaviour to promote the resolution of inflammation. Targeting the citrullinated histone component of - [Employee Spotlight - Stephanie van Dalen](https://citryll.com/employee-spotlight-stephanie-van-dalen/) - Meet Stephanie van Dalen, a scientist at Citryll, and an integral part of our Translational Medicine team, specializing in hidradenitis suppurativa (HS). In her role, she serves as a link between innovative research and clinical practice, collaborating with HS clinicians and external partners to collect essential patient data. - [Exploring the Emerging Role of Extracellular Traps in Immune-Mediated Inflammatory Diseases](https://citryll.com/exploring-the-emerging-role-of-extracellular-traps-in-immune-mediated-inflammatory-diseases/) - Earlier this week, Citryll hosted an educational webinar bringing together leading scientific and clinical experts to discuss the evolving understanding of extracellular traps (ETs) and their emerging role in immune-mediated inflammatory diseases (IMIDs).The webinar explored the growing body of evidence supporting ETs as fundamental drivers of inflammation across multiple disease areas, as well as the - [Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013](https://citryll.com/citryll-strengthens-intellectual-property-portfolio-with-grant-of-european-composition-of-matter-patent-for-cit-013/) - Expected to provide exclusivity into 2039Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), today announces that the European Patent Office has granted a composition of matter patent (EP3841120) covering CIT-013, the Company’s lead drug candidate for the treatment - [First patient dosed in Citryll's imaging study evaluating distribution and target engagement of CIT-013](https://citryll.com/first-patient-dosed-in-citrylls-imaging-study-evaluating-distribution-and-target-engagement-of-cit-013/) - PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in participants with rheumatoid arthritis and hidradenitis suppurativaFindings will be additive to outcomes of ongoing Phase IIa studies in both indications, which launched in 2025Oss, Netherlands – 17 February 2026 – Citryll, a biotech company pioneering a - [Employee Spotlight - Catarina Antunes](https://citryll.com/employee-spotlight-catarina-antunes/) - As a key part of Citryll’s team, Catarina Antunes, Program & Communications Manager, plays a central role in driving cross‑functional projects forward while ensuring our scientific progress is communicated clearly and effectively. Her unique path – from the lab to strategy and communications – offers valuable perspective on the many ways expertise can drive impact - [End of Year Newsletter 2025](https://citryll.com/end-of-year-newsletter-2025/) - As I look back on 2025, it has been a truly remarkable year for the Citryll team. With a laser focus on the clinical development of CIT-013, our first in class monoclonal antibody for the treatment of immune-mediated inflammatory diseases, we have initiated two Phase 2a trials in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS). - [First Patient Dosed In Citryll's Phase IIA Hidradenitis Suppurativa Trial](https://citryll.com/first-patient-dosed-in-citrylls-phase-iia-hidradenitis-suppurativa-trial/) - Multi-center, randomized study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with hidradenitis suppurativaMarks the start of the second Phase IIa trial to evaluate first-in-class monoclonal antibody CIT-013 this year, following the rheumatoid arthritis trialOss, Netherlands – 08 December 2025 – Citryll, a biotech company pioneering a transformative approach to treating - [Citryll presents positive data from phase I study of CIT-013 in Rheumatoid Arthritis at ACR convergence 2025](https://citryll.com/citryll-presents-positive-data-from-phase-i-study-of-cit-013-in-rheumatoid-arthritis-at-acr-convergence-2025/) - Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical activity, and robust biomarker responsesData provides strong validation for the advancement of CIT-013 into Phase IIa studiesOss, Netherlands – 27 October 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), has - [First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis](https://citryll.com/first-patient-dosed-in-citrylls-phase-iia-trial-evaluating-cit-013-in-rheumatoid-arthritis/) - Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces that the first patient has been successfully - [Citryll Announces Formation Of Scientific Advisory Board](https://citryll.com/citryll-announces-formation-of-scientific-advisory-board/) - Board comprises world-renowned experts in biology, immunology and pathology. Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces the formation of its Scientific Advisory Board (SAB). The Board will provide strategic guidance and scientific insight as - [Employee Spotlight – Eline Zwiers](https://citryll.com/employee-spotlight-eline-zwiers/) - Eline Zwiers is a valued member of Citryll’s research team. As a Research Associate, she plays a key role in driving our scientific efforts forward. Her contributions have been instrumental, particularly in our recent work exploring eosinophil extracellular traps (EETs). In one of our latest manuscripts, Eline helped demonstrate that our antibody, CIT-013, targets not - [Employee Spotlight - Katerina Pardali](https://citryll.com/employee-spotlight-katerina-pardali/) - In this edition of our Employee Spotlight series, we’re proud to feature Katerina Pardali, who leads Translational Medicine team - [Reflections on a Transformative Year at Citryll](https://citryll.com/reflections-of-a-transformative-year-at-citryll/) - As we approach the holiday season and the end of 2024, I wanted to take a moment to reflect on what has been a remarkable year for Citryll and share our plans for 2025. - [International Journal of Dermatology Publication: NETs as Targets for Hidradenitis Suppurativa Therapy](https://citryll.com/international-journal-of-dermatology-publication-nets-as-targets-for-hidradenitis-suppurativa-therapy-2/) - Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterised by recurrent, painful skin lesions which may lead to irreversible tissue destruction and extensive scarring. One hallmark of HS lesions is the infiltration and activation of neutrophils, which release proinflammatory and cytotoxic neutrophil extracellular traps (NETs) which are macromolecules consisting of the cell’s DNA, citrullinated histones and the granule contents which normally function to kill and digest microbes. - [Antibodies clamp down on NET nucleosomes](https://citryll.com/antibodies-clamp-down-on-net-nucleosomes/) - In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may find applications in numerous inflammatory conditions. This new antibody, called tACPA, inhibits the completion ... - [Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013](https://citryll.com/citryll-and-lonza-enter-into-partnership-to-manufacture-netosis-inhibiting-antibody-cit-013/) - Oss, The Netherlands and Basel, Switzerland, 9 September 2019 – The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013. - [Citryll collaborates with leading NET researcher Dr. Markus Hoffmann](https://citryll.com/citryll-collaborates-with-leading-net-researcher-dr-markus-hoffmann/) - Oss, The Netherlands, Erlangen, Germany September 18, 2019 —https://citryll.com/ announced today that it has established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University of ... - [Citryll moves to new premises at Pivot Park in Oss, The Netherlands](https://citryll.com/citryll-moves-to-new-premises-at-pivot-park-in-oss-the-netherlands/) - Oss, The Netherlands, October 21, 2019 —www.citryll.com Citryll announced today that it has occupied new office and lab space at the Pivot Park in Oss the Netherlands. - [Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases](https://citryll.com/therapeutic-acpa-inhibits-net-formation-a-potential-therapy-for-neutrophil-mediated-inflammatory-diseases/) - Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed by severe organ damage ... - [Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology](https://citryll.com/landmark-paper-on-citrylls-net-inhibitor-programme-published-in-natures-cellular-and-molecular-immunology/) - Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s Cellular and Molecular Immunology journal, to be found at ... - [Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps](https://citryll.com/citryll-completes-e-18-5-m-fundraise-to-develop-cit-013-an-antibody-targeting-neutrophil-extracellular-traps/) - Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing... - [Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board](https://citryll.com/industry-veterans-paul-peter-tak-and-eric-meldrum-join-citrylls-board/) - We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value... - [Citryll Appoints Chief Medical Officer](https://citryll.com/press-release-citryll-appoints-chief-medical-officer/) - Citryll today announced it has appointed Patrick Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management / Biometrics, and Drug Safety. - [Citryll Appoints CTO and CSO](https://citryll.com/citryll-appoints-cto-and-cso/) - Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer. - [Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies](https://citryll.com/press-release-citryll-appoints-cto-and-cso/) - Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO). - [Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology](https://citryll.com/press-release-citryll-enters-into-bioanalytics-partnership-with-ardena-for-the-clinical-development-of-cit-013-antagonist-of-net-biology-and-associated-pathologies/) - Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. - [Citryll Appoints Sjoerd van Gorp as Director of Operations](https://citryll.com/citryll-appoints-sjoerd-van-gorp-as-director-of-operations/) - Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives. - [Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors](https://citryll.com/citryll-appoints-sjoerd-van-gorp-as-director-of-operations-2/) - Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors. - [Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO ](https://citryll.com/citryll-announces-the-appointment-of-paul-peter-tak-as-chair-of-the-board-of-directors/) - Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards. - [Citryll announces the appointment of Maarten Kraan as Chief Medical Officer](https://citryll.com/citryll-announces-the-appointment-of-maarten-kraan-as-chief-medical-officer/) - Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb. - [Citryll Completes Patient Dosing In The Repeat Dose Stage Of The Phase 1 Trial](https://citryll.com/citryll-completes-patient-dosing-in-the-repeat-dose-stage/) - The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers. - [A Year in Review: An Interview with Citryll's CEO](https://citryll.com/a-year-in-review-an-interview-with-citrylls-ceo/) - Celebrating his first year as CEO of Citryll, Eduardo offers a unique perspective on his journey so far. In this exclusive interview, he reflects on the past year's challenges, achievements, and strategic initiatives that have driven the company forward. - [Citryll and Leading Rheumatology Centres Receive ReumaNederland Grant to Collaborate on NET Research to Advance Novel Treatments for Rheumatoid Arthritis](https://citryll.com/citryll-and-leading-rheumatology-centres-receive-reumanederland-grant/) - Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces a ground-breaking collaboration with leading rheumatology centres of excellence in the Netherlands funded by ReumaNederland (Dutch Arthritis Society). - [Citryll Raises EUR 85 Million Series B To Advance Novel NET-Targeting Therapy For Immune-Mediated Inflammatory Disorders](https://citryll.com/citryll-raises-eur-85-million-series-b-to-advance-novel-net-targeting-therapy-immune-mediated-inflammatory-disorders/) - Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), announces today the successful closing of an oversubscribed EUR 85 million Series B fundraise. - [Employee Spotlight - Dorus Wilderbeek](https://citryll.com/employee-spotlight-dorus-wilderbeek/) - Dorus Wilderbeek, the Sr. Project Manager responsible for Citryll's upcoming Phase 2a clinical trial in Rheumatoid Arthritis, joined our company just five months ago. Today, he is the first member of our team to be invited to our Employee Spotlight series, where he will walk us through his journey in pharma and what lead him to join our company. - [Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders](https://citryll.com/citryll-demonstrates-broader-therapeutic-potential-cit-013-treatment-inflammatory-disorders/) - Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), announces today the successful closing of an oversubscribed EUR 85 million Series B fundraise. - [International Day of Women and Girls in Science](https://citryll.com/international-day-women-girls-science/) - February 11th marks the International Day of Women and Girls in Science. In celebration of this occasion, we invited three scientists at Citryll to reflect on their journeys in science and share their perspectives on women in biotech. Meet Sangeeta Kumari, Tirza Bruurmijn and Annemarie Kip as they discuss their motivations, daily experiences, and advice for the next generation of women in science. ## Pages - [Home](https://citryll.com/) - Citryll is pioneering treatments for immune-mediated inflammatory diseases targeting Neutrophil Extracellular Traps with CIT-013. - [Contact us](https://citryll.com/contact-us/) - Get in touch with Citryll to learn more about our NET-targeting therapies and innovative treatments for immune diseases. Contact us today. - [About Citryll](https://citryll.com/about-citryll/) - Citryll is pioneering innovative treatments for immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps ( NETs) to address the source. - [Publications](https://citryll.com/publications/) - See Citryll latest publications on NETs, inflammation, and CIT-013, showcasing research in immune disease treatment and innovation. - [Latest News](https://citryll.com/latest-news/) - Stay updated with Citryll latest news on NET-targeting therapies, CIT-013 advancements, and breakthroughs in immune disease treatment and research. - [Dual Mechanism of Action](https://citryll.com/cit-013-dual-mechanism-of-action/) - Explore CIT-013 Dual Mechanism of Action targeting NETs to reduce inflammation & enhance clearance, offering a novel approach to treating immune diseases. - [Rheumatoid Arthritis](https://citryll.com/rheumatoid-arthritis/) - Discover how CIT-013 targets NETs to reduce inflammation and treat rheumatoid arthritis, offering an approach to managing this autoimmune disease. - [Clinical Development](https://citryll.com/clinical-developments/) - Learn about CIT-013 clinical development targeting NETs to treat immune diseases with a first-in-class approach to reducing inflammation and improving health. - [Science of ETosis](https://citryll.com/science-of-etosis/) - Discover the science of ETosis and how Neutrophil Extracellular Traps (ETs) contribute to inflammation and how Citryll targets them to treat immune diseases. - [Careers](https://citryll.com/careers/) - Join Citryll and be part of a pioneering team developing NET-targeting therapies to treat immune diseases. Explore our careers opportunities today. - [Patients](https://citryll.com/patients/) - Explore how Citryll innovative therapies target NETs to help patients with immune diseases by reducing inflammation and improving treatment outcomes. - [Hidradenitis Suppurativa](https://citryll.com/hidradenitis-suppurativa/) - Learn how CIT-013 targets NETs to reduce inflammation and provide a new approach to treating hidradenitis suppurativa, a chronic inflammatory skin disease. - [Terms & Conditions](https://citryll.com/terms-conditions/) - Explore Citryll Terms & Conditions to understand the guidelines for using our website, including legal information, user responsibilities, & data usage policies - [Privacy Policy](https://citryll.com/privacy-policy/) - Read Citryll Privacy Policy to learn how we collect, use, and protect your personal data while ensuring your privacy and compliance with regulations. - [Cookie Notice](https://citryll.com/cookie-notice/) - Learn how Citryll uses cookies to enhance your browsing experience. Read our Cookie Notice for details on cookie usage, preferences, and data protection ## Clincial Trials - [Cityview – PET-Based Imaging of Radiolabelled CIT-013](https://citryll.com/clinical-trial/cityview-pet-based-imaging-of-radiolabelled-cit-013/) - [Citylights - A Study With CIT-013 in HS Patients](https://citryll.com/clinical-trial/citylights-a-study-with-cit-013-in-hs-patients/) - [Citydream – A Study with CIT-013 in RA patients](https://citryll.com/clinical-trial/citydream-a-study-with-cit-013-in-ra-patients/) ## Events - [EADV Congress](https://citryll.com/events/eadv/) - [18th European Bioanalysis Forum](https://citryll.com/events/18th-european-bioanalysis-forum/) - [Jefferies Global Healthcare Conference](https://citryll.com/events/jefferies-global-healthcare-conference/) - [6th Inflammatory Skin Disease Summit](https://citryll.com/events/6th-inflammatory-skin-disease-summit/) - [Bio-Europe](https://citryll.com/events/bio-europe/) - [SHSA](https://citryll.com/events/shsa/) - [ACR Convergence](https://citryll.com/events/acr-convergence/) - [Novel Concepts in Innate Immunity](https://citryll.com/events/novel-concepts-in-innate-immunity/) - [EULAR](https://citryll.com/events/eular/) - [BIO International Convention](https://citryll.com/events/bio-international-convention/) - [International Eosinophil Society Congress](https://citryll.com/events/international-eosinophil-society-congress/) - [International Congress of Immunology](https://citryll.com/events/international-congress-of-immunology/) - [European Phagocyte Workshop](https://citryll.com/events/european-phagocyte-workshop/) - [Resolution Days](https://citryll.com/events/resolution-days-frankfurt/) - [Dermatology Drug Development Summit](https://citryll.com/events/dermatology-drug-development-summit-berlin/) - [EWRR](https://citryll.com/events/ewrr-budapest/) - [Bio-Equity](https://citryll.com/events/bio-equity-brugges/) - [ASCPT 2025 Annual Meeting](https://citryll.com/events/ascpt-2025-annual-meeting-washington-dc/) - [AAD Annual Meeting](https://citryll.com/events/aad-annual-meeting/) - [Keystone Symposia: Myeloid Cells](https://citryll.com/events/keystone-symposia-myeloid-cells/) - [EIP Symposium on Immunogenicity of Biopharmaceuticals](https://citryll.com/events/eip-symposium-on-immunogenicity-of-biopharmaceuticals/) - [EHSF Conference](https://citryll.com/events/ehsf-conference/) - [BIO-Europe Spring](https://citryll.com/events/bio-europe-spring/) - [AAD Anual Meeting](https://citryll.com/events/aad-anual-meeting/) - [EHSF Conference](https://citryll.com/events/ehsf-conference-temp/) ## Publications - [Antibody-opsonized extracellular traps modulate macrophage responses and attenuate their T cell-associated inflammatory and costimulatory characteristics](https://citryll.com/publication/antibody-opsonized-extracellular-traps-modulate-macrophage-responses-and-attenuate-their-t-cell-associated-inflammatory-and-costimulatory-characteristics/) - [Immunothrombosis Promotes The Interaction Between Neutrophils And Synovial Fibroblasts In Rheumatoid Arthritis](https://citryll.com/publication/immunothrombosis-promotes-the-interaction-between-neutrophils-and-synovial-fibroblasts-in-rheumatoid-arthritis/) - [Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT 013, a first-in-class extracellular traps targeted therapy](https://citryll.com/publication/phase-i-in-participants-with-rheumatoid-arthritis/) - [Neutrophil extracellular traps in rheumatoid arthritis: biomarkers, drivers, and emerging therapeutic targets](https://citryll.com/publication/neutrophil-extracellular-traps-in-rheumatoid-arthritis/) - [Targeting Neutrophil Function as Therapy for Hidradenitis Suppurativa](https://citryll.com/publication/targeting-neutrophil-function-as-therapy-for-hidradenitis-suppurativa/) - [Neutrophil Extracellular Traps Are Widely Distributed Across Lesional and Perilesional Hidradenitis Suppurativa Skin, and Elevated Serum NET Markers Associate With Moderate to Severe HS Disease](https://citryll.com/publication/neutrophil-extracellular-traps-are-widely-distributed-across-lesional-and-perilesional-hidradenitis-suppurativa-skin-and-elevated-serum-net-markers-associate-with-moderate-to-severe-hs-disease/) - [Anti-Citrullinated Protein Antibodies as Novel Therapeutic Drugs in Rheumatoid Arthritis](https://citryll.com/publication/anti-citrullinated-protein-antibodies-as-novel-therapeutic-drugs-in-rheumatoid-arthritis/) - [Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders](https://citryll.com/publication/inhibition-of-eetosis-with-an-anti-citrullinated-histone-antibody-a-novel-therapeutic-approach-for-eosinophilic-inflammatory-disorders/) - [Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists](https://citryll.com/publication/real-time-high-throughput-microscopic-quantification-of-human-neutrophil-extracellular-trap-release-and-assessing-the-pharmacology-of-antagonists/) - [Anti-citrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases](https://citryll.com/publication/anti-citrullinated-histone-monoclonal-antibody-cit-013-a-dual-action-therapeutic-for-neutrophil-extracellular-trap-associated-autoimmune-diseases/) - [Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases](https://citryll.com/publication/therapeutic-acpa-inhibits-net-formation-a-potential-therapy-for-neutrophil-mediated-inflammatory-diseases/) ## Vacancies - [QA Officer](https://citryll.com/vacancy/qa-officer/) - Role overview: The QA Officer will support the implementation, maintenance, and execution of the Quality Management System (QMS) to ensure the quality and regulatory compliance of the company’s products, processes, and activities. The QA Officer works closely with the QA Manager and cross-functional teams to ensure that quality standards and regulatory requirements are consistently applied ## Clinical Development Timelines - Phase 2a - [Phase 2a in Hidradenitis Suppurativa](https://citryll.com/timeline-phase-2a/phase-2a-in-hidradenitis-suppurativa/) - [Phase 2a in Rheumatoid Arthritis](https://citryll.com/timeline-phase-2a/phase-2a-in-rheumatoid-arthritis/) ## Clinical Development Timelines - Phase 1 - [Repeat dosing In Rheumatoid Arthritis patient volunteers](https://citryll.com/clinical-development/repeat-dosing-in-rheumatoid-arthritis-patient-volunteers/) - [Subcutaneous single dosing in healthy volunteers](https://citryll.com/clinical-development/subcutaneous-single-dosing-in-healthy-volunteers/) - [LPS challenge in healthy volunteers](https://citryll.com/clinical-development/lps-challenge-in-healthy-volunteers/) - [Single ascending dose in healthy volunteers](https://citryll.com/clinical-development/single-ascending-dose-in-healthy-volunteers/) - Q3 2022 - finalized ## Categories - [Uncategorised](https://citryll.com/category/uncategorised/) - [news](https://citryll.com/category/newsitems/) ## Career Categories - [Vacancy](https://citryll.com/career_category/vacancy/) ## Event Categories - [Expired Events](https://citryll.com/event-category/expired-events/)